Comparison of General Practice and Pharmaceutical Dispensing Data for Pharmacoepidemiological Research: Assessing the Risk of Urinary-Tract Infections with Sodium Glucose Cotransporter 2 Inhibitors for Diabetes
Table 2
Other indicators.
MedicineInsight
10 PBS
SGLT2 cohort (N=1977)
SGLT2 cohort (N=3120)
Type of the index medicine
Dapagliflozin – 93
Dapagliflozin – 87
Canagliflozin – 3
Canagliflozin – 9
Empagliflozin – 4
Empagliflozin – 4
Strength at initiation
Dapagliflozin initiators – all on 10mg (one strength)
Dapagliflozin initiators – all on 10mg (one strength)
Canagliflozin initiators – 78 on 300mg (higher strength)
Canagliflozin initiators – 77 on 300mg (higher strength)
Empagliflozin initiators – 74 on 10mg (lower strength)
Empagliflozin initiators – 72 on 10mg (lower strength)
Prior diabetes therapy (prior 12 months)
90 had documented diabetes medicine
80 had dispensing for diabetes medicine
86 had metformin and/or sulfonylurea
69 had metformin and/or sulfonylurea
Interacting medicines (3 months prior and 6 months post index)
